Clinical Trials Browser

NIH × Breast Neoplasms × 30 days × Clear all

NCT00043472 2026-06-05

Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT00451022 2026-06-05

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Prostatic Neoplasms

NCT00469339 2026-06-05

Risk Communication Within Mexican-American Families

BreastGastrointestinal

Breast Neoplasms, Cardiovascular Diseases, Colonic Neoplasms, Diabetes Mellitus

NCT01174121 2026-06-05

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Phase 2 Recruiting

BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03762733 2026-06-05

Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies

Enrolling by invitation

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Uterine Neoplasms

NCT07328516 2026-06-05

Natural History Study of Early Life Exposures in Agriculture (ELEA)

Enrolling by invitation

64,277 enrolled

BreastDermatologicGastrointestinalGenitourinaryOther hematologic neoplasm

Breast Neoplasms, Leukemia, Melanoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT07067138 2026-06-04

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

Phase NA Suspended

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07619534 2026-06-04

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02954874 2026-06-03

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Phase 3 Active not recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00006421 2026-06-01

Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study

Breast Neoplasms

NCT00034216 2026-06-01

Collection of Blood From Patients With Cancer

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Prostatic Neoplasms

NCT00040222 2026-06-01

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

BreastGynecologic

Breast Cancer, Familial, Breast Neoplasms, Hamartoma Syndrome, Multiple, Ovarian Neoplasms, Peutz-Jeghers Syndrome, Li-Fraumeni Syndrome, Risk Reduction Behavior

NCT02595957 2026-06-01

Genomic Services Research Program

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms

NCT03939897 2026-06-01

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Phase 1 Active not recruiting

24 enrolled 15 charts

Breast Neoplasms

NCT06995898 2026-06-01

The Vanguard Study: Testing a New Way to Screen for Cancer

Phase NA Recruiting

24,000 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT00310180 2026-05-29

TAILORx

Phase 3 Active not recruiting

10,273 enrolled 14 charts

Breast Neoplasms

NCT01251900 2026-05-29

BRCA Mutations in Latinas

Breast Neoplasms

NCT02115282 2026-05-29

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Phase 3 Active not recruiting

608 enrolled 18 charts

Breast Neoplasms

NCT02311933 2026-05-29

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Active not recruiting

81 enrolled 9 charts

Breast Neoplasms

NCT03199885 2026-05-29

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Terminated

190 enrolled 13 charts

Breast Neoplasms

NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2 Recruiting

BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

Phase 2 Completed

21 enrolled 21 charts

BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02883062 2026-05-28

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07137416 2026-05-28

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Phase 1 Recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01251874 2026-05-22

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02849496 2026-05-22

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating